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Unknown molecular responses to sarcomere protein gene muta-
tions account for pathologic remodeling in hypertrophic cardiomy-
opathy (HCM), producing myocyte growth and increased cardiac
fibrosis. To determine if hypertrophic signals activated myocyte
enhancer factor-2 (Mef2), we studied mice carrying the HCM
mutation, myosin heavy-chain Arg403Gln, (MHC403/+) and an Mef2-
dependent β-galactosidase reporter transgene. In young, prehyper-
trophic MHC403/+ mice the reporter was not activated. In hypertro-
phic hearts, activation of the Mef2-dependent reporter was re-
markably heterogeneous andwas observed consistently inmyocytes
that bordered fibrotic foci with necrotic cells, MHC403/+ myocytes
with Mef2-dependent reporter activation reexpressed the fetal my-
osin isoform (βMHC), a molecular marker of hypertrophy, although
MHC403/+ myocytes with or without βMHC expression were compa-
rably enlarged over WT myocytes. To consider Mef2 roles in severe
HCM, we studied homozygous MHC403/403 mice, which have acceler-
ated remodeling, widespreadmyocyte necrosis, and neonatal lethal-
ity. Levels of phosphorylated class II histone deacetylases that
activate Mef2 were substantially increased in MHC403/403 hearts,
but Mef2-dependent reporter activation was patchy. Sequential
analyses showed myocytes increased Mef2-dependent reporter ac-
tivity before death. Our data dissociate myocyte hypertrophy, a con-
sistent response in HCM, from heterogeneous Mef2 activation and
reexpression of a fetal gene program. The temporal and spatial re-
lationship ofMef2-dependent gene activationwithmyocyte necrosis
and fibrosis in MHC403/+ and MHC403/403 hearts defines Mef2 activa-
tion as a molecular signature of stressed HCM myocytes that are
poised to die.
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Hypertrophic cardiomyopathy (HCM)-causing mutations inthe myosin heavy-chain gene stimulate myocyte hypertrophy,
disarray, and fibrosis, the pathologic features of HCM (1). Be-
cause germline mutations cause HCM, expression of mutant
sarcomere proteins is predicted to occur in all ventricular myo-
cytes. Nonetheless, the histopathologic manifestations in human
HCM are strikingly heterogeneous, and regions of marked hy-
pertrophic remodeling abut regions with preserved myocardial
architecture. Pathologic remodeling in HCM increases myocar-
dial fibrosis, which reflects expansion of the interstitial matrix and
accumulation of foci of replacement fibrosis (myocardial scarring)
that arise after premature myocyte death (2, 3). Patchy myocyte
death and myocardial scarring in HCM hearts have been attrib-
uted to regional ischemia (4, 5), increased ventricular wall forces
(5), and impaired metabolism (6). Recent data demonstrate
a correlation between the load of focal fibrosis and arrhythmias
(7), an important substrate for sudden death in HCM. Moreover,
myocardial scarring may contribute to the development of heart
failure, which occurs in 10–15% of HCM patients (8).
Definition of the molecules and pathways in HCM that pro-
mote death or enable survival of mutant myocytes has been
hampered by a lack of molecular markers that distinguish pre-
morbid from viable mutant myocytes. To address this conundrum,
we studied a mouse model of HCM that carries a sarcomere gene
mutation, develops pathologic remodeling including myocyte
hypertrophy and increased myocardial fibrosis (9), and exhibits
diastolic dysfunction (10). As in human patients, cardiac fibrosis
in HCM mice is patchy and varies in extent and distribution (11).
The myocyte enhancer factor-2 (Mef2) family of transcription
factors is activated in several myocardial pathologies that are
characterized by hypertrophy and fibrosis (12–15). Mef2 activa-
tion leads to reexpression of some fetal genes (12, 13, 16) that
may provide compensatory adaptations (e.g., metabolic changes)
that promote survival in stressed myocytes (13).
To consider whether Mef2 participates in myocyte responses to
a sarcomere gene mutation, we used a genetic strategy. Mice that
express a humanHCMmutation, myosin heavy-chain Arg403Gln,
(MHC403/+) and a reporter of global Mef2 activity, Mef2-LacZ
(β-galactosidase) (17), were characterized. Although this reporter
can be activated by bothMef2 and Tead transcription factors (18),
transcriptional analyses of MHC403/+ hearts indicated a primal
role forMef2 isoforms in reporter activation. To accentuate stress
from mutant sarcomeres, we also studied homozygous mutant
(MHC403/403) mice that undergo profound and relentless patho-
logic remodeling until death, which consistently occurs by day 10
(3). Our findings revealed marked heterogeneity in Mef2-
dependent reporter activation in mutant myocytes. Activation of
the Mef2-dependent reporter was unrelated to myocyte hyper-
trophy but was closely associated with fetal gene reexpression and
focal pathological remodeling, including myocyte necrosis and
myocardial scarring. Mef2-dependent gene activation provides
a molecular marker that identifies premorbid myocytes and the
presumptive sites of myocardial scarring in HCM.
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Focal Activation of Mef2-Dependent Reporter Adjacent to Fibrotic
Areas in Hypertrophic MHC403/+ Hearts. Cardiac hypertrophy and
pathologic remodeling evolves slowly in MHC403/+ mice, be-
coming overt by age 30 wk (9). Comprehensive analyses of RNAs
showed that ventricular levels of Mef2a, -c and -d isoforms (Table
S1) are unchanged in young, prehypertrophic MHC403/+ and WT
mice (19). With the emergence of hypertrophic remodeling,
ventricular levels ofMef2a andMef2d and phosphorylated class II
histone deacetylases (HDACs), which participate in Mef2 acti-
vation (20–22), increased significantly. In comparison withMef2a,
-c, and -d isoforms, ventricular TEA domain (Tead; isoforms 1–4)
transcripts were expressed at lower levels, were comparable in
prehypertrophic MHC403/+ and WT mice, and were unaltered by
hypertrophic remodeling. From these data, we deduced that ac-
tivation of the Mef2-dependent promoter LacZ transgene (des-
ignatedMef2-LacZ) (17) that occurred in the context of temporal
remodeling in HCM reflected Mef2 activation.
Mef2-LacZ and MHC403/+ mice were bred to generate com-
pound MHC403/+/Mef2-LacZ mice. To assess Mef2-dependent
reporter activity, we initially compared β-galactosidase activity in
3-wk-old MHC403/+/Mef2-LacZ mice and WT mice carrying the
Mef2-LacZ reporter gene (designated WT/Mef2-LacZ). Left
ventricular wall thickness and cardiac histology were normal in
juvenileMHC403/+/Mef2-LacZmice (Table S2). Lightmicroscopy
of X-gal–stained whole hearts and sections revealed comparable
low levels of Mef2-dependent reporter activity (visualized as blue
staining) in MHC403/+/Mef2-LacZ and WT/Mef2-LacZ hearts
(Fig. 1A). Quantitative assessment of total Mef2-dependent re-
porter activity in ventricular lysates showed no difference between
WT and MHC403/+ genotypes (4.5 ± 0.37 U/mg and 6.8 ± 1.2 U/
mg, respectively, P = not significant) (Fig. 1B).
At age 30 wk, MHC403/+/Mef2-LacZ mice had increased ven-
tricular wall thickness (Table S2) and typical HCM cardiac his-
topathological abnormalities, while age-matchedWT-Mef2-LacZ
hearts were normal. X-gal–stained whole hearts and myocardial
sections of MHC403/+/Mef2-LacZ mice showed more Mef2-
dependent reporter activity with strikingly focal staining than seen
in whole hearts and myocardial sections of WT/Mef2-LacZ mice
(Fig. 1A). Quantitative assessments revealed 1.5-fold greater
Mef2-dependent reporter activity (Fig. 1B) in hypertrophic
MHC403/+/Mef2-LacZ ventricles (12.6 ± 1.6 U/mg) than in WT/
Mef2-LacZ ventricles (8.1 ± 0.15 U/mg; P = 0.03).
We compared the pattern of Mef2-dependent reporter activa-
tion and histological abnormalities in left ventricular sections of
hypertrophic 30-wk-old MHC403/+/Mef2-LacZ mice and age-
matched WT/Mef2-LacZ mice, using X-gal (dark blue) and
Gomori trichrome (light blue) stains, which detect collagen that
accompanies fibrosis. Hypertrophic MHC403/+/Mef2-LacZ hearts
exhibited clusters of myocytes with activated Mef2-dependent
reporter, which were juxtaposed to every focal region of myo-
cardial scarring [Fig. 2 A (see c, e, and f) and B]. In contrast, only
isolated myocytes with Mef2-dependent reporter activity were
detected in WT/Mef2-LacZ hearts (see a and b in Fig. 2A) and in
nonscarred regions of hypertrophic MHC403/+/Mef2-LacZ hearts
(see d in Fig. 2A). The distribution of clustered myocytes with
Mef2-dependent reporter activation varied among mice and
showed no consistent pattern within left ventricular segments
(e.g., septum, free wall, or apex).
Because focal fibrosis or microscopic myocardial scars are as-
sumed to emerge aftermyocyte death,we asked ifMef2-dependent
reporter activation was associated with myocyte demise. Ventric-
ular sections from hypertrophic MHC403/+/Mef2-LacZ hearts
were reacted with von Kossa stain, which detects secondary dys-
trophic calcification, a surrogate marker of necrotic cell death.
Over 50 fibrotic areas from hearts of MHC403/+/Mef2-LacZ mice
that weremore than 30 wk old (n= fourmice and>20 sections per
mouse) were studied. Myocytes with Mef2-dependent reporter
activity clustered around von Kossa staining (see b in Fig. 2B) in
MHC403/+/Mef2-LacZ hearts, and revealed a close association of
Mef2-dependent reporter activity, focal necrosis with dystrophic
calcification, and scar (see a and b in Fig. 2B; X-gal plus Gomori
trichrome staining and X-gal plus von Kossa staining).
Previous studies demonstrated that focal fibrosis occurs in aging
WT mouse hearts (23). Consistent with these data, we observed
Fig. 1. Cardiac Mef2 activation in 30-wk-old MHC403/+/Mef2-LacZ mice (403/+)
and WT/Mef2-LacZ mice (WT). (A) Whole heart and sections from mice (age 3
and 30 wk) stained with X-gal to assess β-galactosidase activity (stained blue).
Left ventricles of 30-wk-old MHC403/+ mice had increased, patchy Mef2 acti-
vation compared with WT hearts. (Scale bars: 1 mm.) (B) β-Galactosidase
activity in 3- and 30-wk-old MHC403/+ mouse ventricles compared with age-
matched WT hearts (n = 3–4 per group).
Fig. 2. Focal Mef2-reporter activation in myocytes adjacent to regions of
myocardial scarring in hypertrophic MHC403/+ mice. (A) Sections from 30-wk-
oldWT/Mef2-LacZ hearts (WT) andMHC403/+/Mef2-LacZ hearts (403/+) stained
with X-gal and Gomori trichrome show increased Mef2-dependent reporter
activity (dark blue) adjacent to regions of fibrosis (light blue) in 403/+ hearts
(c, e, and f) compared with WT hearts (a and b). Nonclustered Mef2-de-
pendent reporter activity was detected in nonfibrotic regions in 403/+ hearts
(d). (Scale bars: 100 μm.) (B) Colocalization of Mef2-dependent reporter ac-
tivity with fibrosis (a) and necrosis (b) in 30-wk-oldMHC403/+/Mef2-LacZ hearts
(403/+). Adjacent sections were stained with Xgal staining followed by
Gomori trichrome staining (a) and von Kossa staining (b). (Scale bars: 100 μm.)
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modest activation of the Mef2-dependent reporter near fibrotic
regions in 60-wk-old WT/Mef2-LacZ hearts (Fig. S1).
βMHC Expression in Hypertrophic MHC403/+/Mef2-LacZ/βMHC-YFP
Hearts. The cardiac fetal myosin isoform, βMHC, a molecular
marker of hypertrophy, can be induced with Mef2 activation (24).
To determine if the βMHC gene was reexpressed selectively in
mutant myocytes with Mef2-dependent reporter activation, we
crossed MHC403/+/Mef2-LacZ mice with transgenic mice that
express YFP under control of the βMHC promoter (βMHC-YFP
mice) (23). Myocytes expressing YFP were found in regions of
myocardial scarring (detected by wheat germ agglutinin; WGA)
(Fig. 3A). To investigate whether MHC403/+ myocytes expressing
YFP were more hypertrophic than YFP-negative myocytes, cell
sizes were assessed. The average cross-sectional area of myocytes
from 30-wk-old MHC403/+/Mef2-LacZ/βMHC-YFP mice was
greater than that of age-matched WT myocytes (Fig. 3B), but
there was no significant difference in the area of YFP-positive
MHC403/+ myocytes and YFP-negative MHC403/+ myocytes (Fig.
3C). In addition, distribution and dispersion of cross-sectional
areas was similar in YFP-positive MHC403/+ myocytes and YFP-
negative MHC403/+ myocytes (Fig. S2).
To determine if activatedMef2 and βMHCwere coexpressed in
the samemyocyte, we assessed colocalization of YFP and LacZ in
30-wk-old MHC403/+/Mef2-LacZ/βMHC-YFP hearts. More than
90% of myocytes that activated theMef2-dependent reporter also
expressed βMHC-promoted YFP (Fig. 3 D and E), whereas 62%
of YFP-positive cells coexpressed the Mef2-dependent reporter
(Fig. 3 D and E).
We concluded thatMef2 activation and βMHCexpression occur
in a subset of MHC403/+ myocytes, independent of hypertrophic
size, and that clusters of myocytes with Mef2 activation are juxta-
posed to foci of fibrosis in MHC403/+ hearts.
Phosphorylation of Class II HDAC in MHC403/+ and MHC403/403 Hearts.
Calcium/calmodulin-dependent protein kinase II and protein ki-
nase D participate in Mef2 activation by phosphorylating the re-
pressor of Mef2, class II HDACs (20–22). We assessed
phosphorylation of class II HDACs in response to the MHC403
mutation by analyzing HDAC5 Serine 498 phosphorylation in
hearts from 6-d-oldWT,MHC403/+, andMHC403/403 mice. At this
age WT and MHC403/+ mice have normal cardiac histology, but
homozygous MHC403/403 mice have rampant cardiomyopathy
with extensive pathologic remodeling and heart failure that causes
death by postnatal day 10 (3). Western blots (Fig. 4 A and B)
showed comparable levels of phosphorylated HDAC5 in young
WT and MHC403/+ hearts but significantly elevated levels in ho-
mozygous MHC403/403 hearts (WT vs. MHC403/403, P = 0.0046;
MHC403/+ vs. MHC403/403, P = 0.0032).
HDAC5 Serine-498 phosphorylation also was assessed in
hearts from 3-wk-old and 30-wk-oldWT andMHC403/+mice (Fig.
S3). Phosphorylated HDAC5 levels were indistinguishable in 3-
wk-old WT and MHC403/+ hearts, but at 30 wk, when hypertro-
phic remodeling is evident in MHC403/+ hearts, phosphorylation
levels of HDAC5 was significantly increased in MHC403/+ hearts
compared with WT hearts (P = 0.03).
Mef2-Dependent Reporter Activation and Myocyte Necrosis in
Homozygous MHC403/403 Hearts. Given the markedly increased
phosphorylated HDAC5 in MHC403/403 mice, we assessed Mef2-
dependent reporter activation in MHC403/403/Mef2-LacZ mice.
Six-day-old homozygous mutant mice had more X-gal staining
(Fig. 4C) and 4.8-fold increased β-galactosidase activity (Fig. 4D)
Fig. 3. Colocalization ofMef2-dependent reporter activity and fetal gene reexpression inMHC403/+myocytes adjacent to amyocardial scar. (A) βMHC reexpression
(identified by YFP) occurred in regions of myocardial scars (identified byWGA) in 30-wk-oldMHC403/+/Mef2-LacZ /βMHC-YFP hearts (403/+). Right shows magnified
view of boxed area in Left. (Scale bars: 100 μm.) (B) Cross-sectional areas of myocytes from 30-wk-old WT/Mef2-LacZ/βMHC-YFP hearts (WT cells; open bar) and
MHC403/+/Mef2-LacZ /βMHC-YFP hearts (403/+ cells; black bars) irrespective of their fluorescence. (C) Cross-sectional areas of the 403/+ cells grouped according to
their YFP fluorescence (YFP- and YFP+, respectively). Over 200 cells per group were analyzed. (Fig. S2 shows distribution of cross-sectional areas of YFP− cells and
YFP+ cells.) (D) Colocalization ofMef2-dependent reporter activity and βMHC-YFP reexpression in 30-wk-oldMHC403/+/Mef2-LacZ/βMHC-YFP hearts. Themajority of
cells are positive for both Mef2-dependent reporter activity and βMHC-YFP; few cells express only one. Lower row shows boxed areas in upper rows at higher
magnification. (Scale bars: 100 μm.) (E) Quantitative assessment of Mef2-dependent reporter activity and βMHC-YFP expression in 256 myocytes; 92% (236
myocytes) coexpressed theMef2-dependent reporter and βMHC-YFP. Blue, myocytes positive only for Mef2-dependent reporter activity; green, myocytes positive
only for βMHC-YPF; black, myocytes positive for both.











than eitherWT/Mef2-LacZ orMHC403/+/Mef2-LacZ hearts (WT
vs. MHC403/403, P = 0.0054; MHC403/+ vs. MHC403/403, P =
0.0057). Even when the dosage of mutant myosins was doubled,
β-galactosidase activity was not found in all MHC403/403 myocytes.
The rapidly progressive cardiomyopathy of MHC403/403 mice
afforded the opportunity to assess the temporal relationship of
Mef2-dependent reporter activation and myocyte necrosis. Histo-
pathologic sections of 3-d-old WT/Mef2-LacZ, MHC403/+/Mef2-
LacZ, and MHC403/403/Mef2-LacZ hearts showed no dystrophic
calcification, a marker of necrosis (Fig. 5 A–F). Mef2-dependent
reporter activity was virtually absent from WT/Mef2-LacZ and
MHC403/+/Mef2-LacZ hearts (Fig. 5 A and B), but focal activation
of the Mef2-dependent reporter occurred in MHC403/403/Mef2-
LacZ hearts (Fig. 5 C–F). At postnatal day 6, WT/Mef2-LacZ and
MHC403/+/Mef2-LacZ hearts lacked detectable Mef2-dependent
reporter activity or necrosis (Fig. 5 G and H). However, 6-d-old
MHC403/403/Mef2-LacZ hearts had abundant, patchy Mef2-
dependent reporter activity in myocytes surrounding necrotic foci
(Fig. 5 I–L and Fig. S4) and in myocytes without nearby necrosis
(Fig. 5I). Based on the consistent activation of Mef2-dependent
reporter in advance of necrotic death of MHC403/403 myocytes and
the colocalization of activated Mef2-dependent reporter, fibrosis,
and myocyte necrosis in MHC403/+ hearts, we concluded that ac-
tivation of the Mef2-dependent reporter delineated profoundly
stressed mutant ventricular myocytes at risk for premature death.
Atrial Activation of the Mef2-Dependent Reporter. The Mef2-
dependent reporter also was activated in atria from 6-d-old
MHC403/403 and hypertrophic MHC403/+ mice. Atrial activation of
the reporter was absent in 6-d-old WT/Mef2-LacZ and MHC403/+/
Mef2-LacZ hearts (Fig. S5 A and B) but was robust in left and right
atria of 6-d-old MHC403/403/Mef2-LacZ mice (Fig. S5 C–F). Mef2-
dependent reporter activation occurred occasionally in atrial myo-
cytes from 30-wk-old WT/Mef2-LacZ mice (Fig. S5 G and H),
but was substantially greater in atrial myocytes from hypertrophic
MHC403/+/Mef2-LacZ hearts (Fig. S5 I–L). Unlike ventricular
specimens, therewasneitherdystrophic calcificationnor focalfibrosis
nearby atrial myocytes with Mef2-dependent reporter activation.
Discussion
We demonstrate markedly heterogeneous activation of an Mef2-
dependent reporter in myocytes with the HCM mutation
MHC403. Activation of Mef2 correlated with reexpression of the
fetal myosin isoform βMHC but was independent of the hyper-
trophic size of mutant ventricular myocytes. InMHC403/403 hearts,
temporal activation of the Mef2-dependent reporter preceded
ventricular myocyte death, but in MHC403/+ hearts Mef2-de-
pendent reporter activation in ventricular myocytes was closely
associated with foci of necrosis and replacement fibrosis. To-
gether these data define Mef2 activation in HCM as a molecular
marker of stressed myocytes that are at risk for premature death.
As such, Mef2-dependent gene activation in the HCM heart often
occurs in regions destined to develop focal myocardial scarring,
a histopathologic hallmark of this cardiomyopathy.
Heterogeneous Mef2 Activation in HCM. Unexpectedly we found
that a germline HCMmutation in genetically inbred mice elicited
different transcriptional response in myocytes throughout the
myocardium. Mef2-dependent gene activation in HCM hearts
was not global but occurred in random patches, a finding that
suggests three conclusions. First, because hypertrophicMHC403/+
myocytes had comparable size regardless of Mef2-dependent re-
porter activation or βMHC expression, myocyte growth signals in
HCM appear to be independent of an Mef2 transcriptional pro-
gram. Second, that Mef2 activation occurred in variable ventric-
ular locations of identical mice suggests that regional parameters,
such as intrinsic coronary vasodilator reserve (25) or hemody-
namic forces (5), are unlikely to drive myocyte death and the
subsequent emergence of microscopic myocardial scarring in
HCM hearts. Third, the substantial concordance between acti-
vation of Mef2-dependent reporter and expression of the fetal
βMHC isoform provided the potential for a direct benefit to HCM
myocytes: dilution of the amount of mutant protein within the
sarcomere and an associated reduction in adverse cellular con-
sequences. Nevertheless, Mef2-dependent gene activation in
Fig. 4. Increased phosphorylation of HDAC5 and Mef2-dependent reporter
activity in MHC403/403 hearts. (A) Western blots of heart lysates from 6-d-old
WT, MHC403/+ (403/+), and MHC403/403 (403/403) mice, reacted with anti-
bodies specific for HDAC5 serine-498, total HDAC5, and GAPDH. (B) Phos-
pho-HDAC5 was normalized to total HDAC5 (n = four to five mice per
group). (C) X-gal–stained (blue) hearts from 6-d-old WT/Mef2-LacZ (WT),
MHC403/+/Mef2-LacZ (403/+), and MHC403/403/Mef2-LacZ (403/403) mice.
MHC403/403/Mef2-LacZ hearts had heterogeneous and greater activation of
the MEF2-dependent reporter than WT and MHC403/+ hearts. (Scale bar: 1
mm.) (D) β-Galactosidase (β-gal) activity (Materials and Methods) measured
in hearts from 6-d-old WT/Mef2-LacZ (WT), MHC403/+/Mef2-LacZ (403/+), and
MHC403/403/Mef2-LacZ (403/403) mice. β-Galactosidase activity was signifi-
cantly increased in MHC403/403 hearts compared with WT and MHC403/+
hearts (n = three per group).
Fig. 5. Mef2-reporter activity is associated with necrotic tissue in homozy-
gous MHC403/403 hearts. Sections from 3-d-old hearts fromWT/Mef2-LacZ (A),
MHC403/+/Mef2-LacZ (B), and MHC403/403/Mef2-LacZ mice (C–F) and 6-d-old
hearts from WT/Mef2-LacZ (G), MHC403/+/Mef2-LacZ (H), and MHC403/403/
Mef2-LacZ mice (J–L) stained with X-gal (blue) and von Kossa stain (brown).
A representative 3-d-old MHC403/403/Mef2-LacZ mouse heart (C–F) demon-
strated that activation of the Mef2-dependent reporter occurred before
onset of necrosis. Focal Mef2-dependent reporter activity without necrosis
also was detected in 6-d-old MHC403/403 hearts (J). Note that necrosis oc-
curred in the myocardium where the Mef2-dependent reporter had been
activated in 6-d-old MHC403/403 hearts (K and L). Other images from 6-d-old
MHC403/403 hearts are shown in Fig. S4. (Scale bars: 100 μm.)
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myocytes was closely associated with ventricular myocyte death,
indicating inadequate compensation to the stress imposed by
a sarcomere gene mutation (Fig. 6). We assume that the pathways
involved in pressure-overload activation of the fetal βMHC iso-
form (23) also participate in activation of Mef2.
Mef2 Pathway to Myocardial Necrosis and Scarring in HCM. Pre-
mature death of myocytes and replacement by focal myocardial
scar is widely recognized in human HCM and in model organisms
(2, 3), but molecules that promote death or survival in mutant
myocytes have not been identified previously. Our data define
Mef2 activation as a marker that distinguishes HCM myocytes.
Although the intrinsic level of Mef2 activity in myocytes may be
more pervasive than is measured by the reporter construct used
here, the Mef2-dependent reporter provided a critical tool for
differentiating mutant myocytes. Ventricular myocytes with
Mef2-dependent reporter activation were consistently juxtaposed
to foci of necrotic myocyte cells (Fig. 2 and Fig. 5 I–L), implicating
Mef2 activation as a molecular barometer of stress in HCM
myocytes. A similar role has been postulated in other cardiac
pathologies (12). That Mef2-dependent reporter was activated
before widespread myocyte death in homozygous MHC403/403
hearts (Fig. 5 I–L) further supports this model. Moreover, the
correlation between levels of Mef2-dependent reporter activation
and mutation dosage suggests that stress is graded within myo-
cytes, because activation was substantially less in hearts carrying
a single mutant allele of myosin than in hearts with two mutant
alleles. By extrapolation to human HCM, we predict that Mef2-
dependent gene activation would be particularly high in myocytes
with compound sarcomere gene mutations that produce severe
histopathology and an associated deleterious clinical course (1,
26). Defining cell and molecular properties of myocytes with ro-
bust Mef2 activation therefore may inform opportunities to re-
duce stress and promote survival in HCM.
Two major cardiac Mef2 isoforms, Mef2a and Mef2d, were in-
creased in response to the MHC403 mutation (Table S1). Although
either isoform, or both, would account for the activation of the
Mef2-dependent reporter used in these studies, the increased acti-
vation of Mef2a or Mef2d might have different consequences on
HCMhearts. TheMHC403mutation produces profound biophysical
changes within the sarcomere (27, 28), alters myocyte handling of
calcium (29), and produces a wide range of molecular and cellular
responses (19) that increase energy demands in HCM hearts (28).
Increased transcription of Mef2a could provide metabolic com-
pensation for these intrinsic stresses by regulating mitochondrial
biogenesis (15), regulating the insulin-responsive glucose trans-
porter type 4 (30), and activating genes that enable myocytes to use
glucose instead of fatty acids for energy production (12, 13, 16).
Myocytes with sarcomere mutations also engender responses in
their local milieu, including expansion of the interstitial matrix.
Mef2d has been implicated in transcriptional activation of genes
encoding extracellular matrix proteins, including connective tis-
sue growth factor and procollagen (types I and III) (13). Remod-
eling of the interstitium may lead to impaired myocyte relaxation
and increased hypoxia due to decreased capillary density and in-
creased oxygen diffusion distances (25, 28). Alternatively, remod-
eling of the extracellular matrix may be beneficial in HCM, as has
been demonstrated in wound healing (31).
Whether Mef2 provides adaptive or maladaptive responses in
HCM likely depends on isoform involvement and duration of ac-
tivation. The robust activation of the Mef2-dependent reporter in
atria that occurred without myocyte necrosis (Fig. S5 I–L) implies
adaptive responses. However, because other models have dem-
onstrated that continued Mef2-dependent gene activation is dele-
terious (13), we speculate that prolonged Mef2 activation
contributes to pathologic atrial remodeling that occurs in both
HCMmice (3, 9) and human patients (32). In contrast to activation
in atrial myocytes, ventricular Mef2-dependent gene activation
occurred in myocytes that were closely associated with focal ne-
crosis and myocardial scarring (Figs. 2B and 5 I–L). Even adaptive
Mef2-dependent gene activation may be inadequate to compen-
sate for the stress of sarcomere gene mutations in ventricular
myocytes, which, because of higher ventricular force, probably are
subject to greater stress than atrial myocytes. We suggest that
balance between the duration of Mef2 activation and myocyte
stress is critical inmyocyte survival or death inHCMhearts (Fig. 6).
An important and unresolved question is why Mef2-dependent
gene activation was strikingly inhomogeneous. Somatic differ-
ences in allelic expression of the mutant gene or in post-
transcriptional regulation of mutant mRNAs and protein might
alter the level of dominant mutation in myocytes. Different levels
of molecules that respond to sarcomere gene mutations [i.e.,
calcium-handling proteins, proteins involved in energetics, and
growth factors (19)] also might compensate for or exacerbate the
consequences of HCM mutations in myocytes. Alternatively,
paracrine signaling by growth factors (i.e., TGF-β) derived from
interstitial cardiac fibroblasts may influence Mef2 activation in
myocytes (33). Regardless of the mechanism leading to Mef2
activation, we suggest that patchy Mef2 activation involves class
II, specifically HDAC5, phosphorylation (Fig. 4), because in-
creased HDAC5 phosphorylation was observed in both hyper-
trophic MHC403/+ and MHC403/403 hearts. With Mef2-dependent
gene activation as a molecular tool to discriminate between
healthy and stressed mutant myocytes, definition of cellular
responses that result in pathologic remodeling from sarcomere
gene mutations will be feasible.
In conclusion, Mef2-dependent gene activation is not the pri-
mary molecular trigger for hypertrophy in HCM but rather is
a signature of focal stress. Mef2-dependent gene activation
defines myocytes in which pathways leading to myocyte death and
focal myocardial scarring, a major histopathologic feature of
HCM, have been activated. Studies to determine if inhibition or
Fig. 6. A pathway from mutation to focal fibrosis in HCM. Mutant sarco-
mere proteins trigger hypertrophy in most myocytes (broad arrow). Stressed
myocytes activate Mef2 and express downstream target genes including
βMHC. When Mef2-dependent gene activation inadequately compensates
for stresses, myocytes die (necrosis), and focal myocardial scars emerge.
Prolonged activation of Mef2-dependent genes fosters survival (34) but may
become maladaptive (13), contributing to pathological remodeling. Accu-
mulation of focal fibrosis (33, 35) may promote adverse outcomes in HCM,
including heart failure and arrhythmias.











activation of Mef2a and Mef2d can attenuate pathological
remodeling may provide new clues regarding the susceptibility to
arrhythmias and development of heart failure in HCM.
Materials and Methods
Mouse Models. Heterozygous MHC403/+ mice and homozygous MHC403/403
mice have been described previously (3, 9, 29). Mef2-LacZ mice carrying a LacZ
transgene controlled by three tandem copies of the Mef2 binding site (17)
and βMHC-YFP mice carrying YFP knocked in to the βMHC locus have been
described previously (23). MHC403/+/Mef2-LacZ, MHC403/403/Mef2-LacZ, and
MHC403/+/Mef2-LacZ/βMHC-YFP mice were derived by mating mutant strains.
All mice were maintained according to protocols approved by the In-
stitutional Animal Care and Use Committee of Harvard Medical School.
Assessment of β-Galactosidase Activity and Histochemical Analyses. Total Mef2
activity in ventricular tissue extracts from WT/Mef2-LacZ, MHC403/+/Mef2-
LacZ, and MHC403/403/Mef2-LacZ mice were determined by a qualitative
histochemical assay. Hearts were fixed in 2% paraformaldehyde/0.2% glu-
taraldehyde in PBS on ice for 60 min and then were immersed overnight at
37 °C in β-galactosidase staining solution [5 mM ferrocyanide, 5 mM ferri-
cyanide, 2 mM MgCl2, 1 mg/mL X-gal (5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside) in dimethylformamide]. Heart tissues subsequently were
processed for histopathological analyses. Paraffin-embedded sections were
stained with either Gomori trichrome to detect collagen or von Kossa stain
to detect secondary dystrophic calcification associated with necrotic tissue.
Quantitative measurements of β-galactosidase activity (14) were made with
the β-galactosidase assay kit (Stratagene).
The βMHC-YFP fusion protein was detected by fluorescence. Heart tissues
from βMHC-YFP mice were embedded in the optimal cryo temperature com-
pound on dry ice. Sections (10 μm) were cut at −20 °C and mounted on
Superfrost Plus microscope slides. βMHC-YFP protein expression and myocar-
dial scarringwas assessed for colocalization in sections stainedwithfluorescent
WGA, labeled with Alexa Fluor 599 (Invitrogen), and images were acquired
with a Leicamicroscope. βMHC-YFP andMef2-LacZ expressionwas visualized in
the same section by LacZ staining (light microscopy) and by detecting YFP
signal with fluorescence microscopy.
Cross-Sectional Areas of Myocytes. IndividualYFP-βMHC–positive and –negative
myocytes were visualized in WGA-stainedMHC403/+/MEF2-LacZ/βMHC-YFP heart
sections, and their cross-sectional area was measured by ImageJ software as
described previously (23). Myocytes from age- and gender-matched WT mice
were studied in parallel.
Immunoblot Analyses. Western blots were performed as described previously
(3, 14), using primary antibodies rabbit anti-phospho-HDAC5 (1:500; Abcam)
and rabbit anti-total HDAC5 (1:100; Cell Signaling Technology).
Statistical Analysis. Data were expressed as means ± SE. Differences between
groups were determined by unpaired Student’s t test or one-factor ANOVA.
A P value <0.05 was considered statistically significant.
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